· Published by Health Canada · Official notice
This is duplicated text of a letter from Medtronic of Canada Ltd.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 30, 2005
Subject: Important patient management information
Dear Doctor,
In accordance with Medtronic's commitment to keeping you informed about the performance of our products, we write to advise you about an issue with a specific subset of Sigma® series pacemakers that may fail due to separation of interconnect wires from the hybrid circuit. This failure mechanism may present clinically as loss of rate response, premature battery depletion, intermittent or total loss of telemetry, or no output. There have been no reported patient injuries or deaths due to this issue.
Medtronic has communicated this information to Health Canada.
There are approximately 1,400 of the affected devices distributed in Canada, out of an initial implant population of 40,000 worldwide. The specific model and serial numbers of affected devices are available online at Medtronic web site.
Separation of redundant interconnect wires has been observed on hybrid terminal blocks. Device failure occurs only where both interconnect wires separate from a hybrid terminal block. In October 2005, we completed testing and analysis identifying the root cause of these failures and the affected population. Hybrid circuits used in this subset of devices were cleaned during manufacturing with a particular cleaning solvent that could potentially reduce the strength of the interconnect wire bond over time.
As part of the ongoing returned product analysis, Medtronic has observed 19 devices from the above population, approximately 0.05%, that have exhibited this failure mechanism. There is no provocative testing that can predict which devices may fail. Implant duration for the 19 failures ranged from 17-38 months. Our modeling predicts a failure rate from 0.17% to 0.30% over the remaining lifetime of these pacemakers.
Medtronic realizes that each of your patients is unique, and supports your clinical judgment in caring for them. To assist physicians in their patient care and after discussion with our physician consultants, Medtronic offers the following recommendations:
Medtronic regrets the difficulties this may cause you and your patients. Medtronic will provide you with regular updates on the ongoing actual performance in our Product Performance Report, available at Medtronic web site.
Should you elect to replace a device for a specific patient, Medtronic will provide a replacement device at no cost. Medtronic's Customer Service Representative at 1-800-268-5346 is available to assist you with this or other issues.
The information in this letter will be posted on the Medtronic web site on December 5, 2005.
If you have any questions, or if Medtronic can be of further assistance, please contact your local Medtronic Representative.
Medtronic of Canada Ltd.
6733 Kitimat Road
Mississauga, Ontario L5N 1W3
Tel.: 1-800-268-5346
Any suspected adverse incident can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
Email: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
Sincerely,
original signed by
Paul Devereaux
Vice President,
Cardiac Rhythm Management
MEDTRONIC OF CANADA LTD.